Scoop on UK's No to the UPC was the most-read IAM story in H1 2020
IAM had 253,953 individual users between 1st January and 30th June, putting us on course for more than 500,000 in total for this year. Between them, users had over 400,000 sessions, with two page views per session on average. Each session lasted an average of one minute 39 seconds. All these numbers are up year on year which, during such an uncertain period and with so many people unable to follow their normal working patterns, is immensely gratifying. We are hugely grateful to all our readers for their support during these very challenging times.
Not surprisingly, our covid-19 coverage features heavily in the list of the top 20 most read stories, but sitting in top position is the story we broke on the British government decision that that UK would not be a part of the unitary patent and Unified Patent Court system. The full top 20 is as follows:
- The UK will not be part of the UPC, government confirms to IAM
- The key covid-19 compulsory licensing developments so far
- The danger COVID-19 presents to biopharma patent owners
- Gilead downplays Chinese lab’s coronavirus patent
- Huawei, Samsung and LG are top owners of ‘core’ 5G patents so far, new study claims
- No strings Covid-19 IP pledge initiative underlines delicate balance biopharma businesses must strike
- The impact of Covid-19 will be felt across the global IP market
- Aon takes a big step forward in IP insurance
- Another big name exit from the Microsoft IP team revealed
- Todd Dickinson - a tribute
- New Ericsson report highlights 5G forces set to shape patent monetisation market
- The USPTO's guidance on patent eligibility is a policy over legal doctrine, says Lemley
- Revealed - Huawei patent disposal to one of the US's most active NPEs
- Global IP Awards winners for 2020 named in London
- “Aggregate licensees, don’t do other stuff” - why it’s Dan McCurdy’s RPX now
- Why price differentiation is key to setting patent royalty rates for 5G
- Why the traditional US model of educating tomorrow’s lawyers must change
- Wuhan lab says it will seek patent protection of Gilead antiviral
- World leaders hatch further plans for accessibility of covid-19 IP rights
- Iancu makes US concerns about possible Chinese WIPO leadership clear